Beijing Biobank and Chongqing Pharma Vientech Enter Strategic Partnership to Advance Biomedical Innovation
On the afternoon of July 11,The strategic cooperation signing ceremony between the Beijing Institute of Life Sciences Biotechnology Research (Beijing Biobank) and Chongqing Medicine Wanwei was successfully held at the Life Science Park in Changping District, Beijing.
He Wen, Deputy General Manager of the Northern Sales Headquarters of Chongqing Pharmaceutical Group; Liang Jiubo, Party Branch Secretary, Executive Director, and General Manager of Chongqing Wanwei (Beijing) Pharmaceutical Co., Ltd.; Wang Fan, Executive Deputy General Manager; and other delegates visited the Research Institute and signed a strategic cooperation agreement. Jin Yi, Director of the Pharmaceutical and Health Industry Division of the Future Science City Management Committee (Life Science Park Management Committee); Yang Weiwei, Director of the Life Science Services Division; and Zhang Xin, Deputy Director of the Life Science Services Division, attended and witnessed the signing ceremony. Zhang Lei, General Manager of Beijing Life Science Park Biotechnology Research Institute; Fan Kefang, Deputy General Manager; and heads of relevant departments also attended the signing ceremony.
First, General Manager Zhang Lei extended a warm welcome to Deputy General Manager He Wen and her delegation. He then led them on an onsite tour of the Beijing Biobank, providing a detailed introduction to its development history and current operational status. Mr. Zhang stated that Zhongyao Wanwei is a key strategic partner of the Beijing Biobank, expressing hope that both parties will fully leverage their respective strengths in the future to support the innovative development of the biobank and the biopharmaceutical industry.
Director Jin Yi first extended warm congratulations on the strategic partnership between the Beijing Biobank and Chongqing Medicine Wanwei, and provided a detailed introduction to the current development status and future plans of the Life Science Park. He expressed hope that the strong alliance between the two parties would achieve new breakthroughs in the translation and utilization of biological samples, as well as in the sustainable development of biobanks.
Deputy General Manager He Wen first provided a detailed overview of the current development status of Chongqing Pharmaceutical Group, and expressed the hope that the strategic cooperation with the Beijing Biobank would extend their collaborative network across China, thereby making positive contributions to the innovative biopharmaceutical industry.
Secretary Liang Jiubo stated that the strategic partnership between Chongqing Medicine Wanwei and the Beijing Biobank is merely a starting point. Moving forward, Chongqing Medicine Wanwei will fully leverage its advantages in third-party services for a comprehensive range of medical devices to engage in deeper and more long-term collaboration with the Beijing Biobank across various business areas.
Subsequently, at the signing ceremony, witnessed by the attending guests, Beijing Biobank and Chongqing Medicine Wanwei successfully signed a strategic cooperation agreement, officially announcing the establishment of their strategic partnership.
Beijing Life Science Park Biotechnology Research Institute (hereinafter referred to as the “Institute”) (Biobank of Life Science Park, abbreviated as “BoLSP”) is a third-party public service platform for biobanking, jointly supported by the Beijing Municipal Science & Technology Commission and Zhongguancun Life Science Park. Building on over a decade of development achievements of the Beijing Biobank of Clinical Resources (hereinafter referred to as the “Beijing Biobank”) (BBCR) and consolidating professional consensus among numerous clinical sample experts, the Institute is committed to serving as a bridge between holders of biological sample resources and researchers in the fields of life sciences and biomedical research, thereby addressing issues such as information asymmetry across the upstream and downstream sectors of biological sample resource development and difficulties in resource sharing.
The Institute has established a 2,000 m² biobank at the Changping Campus of Zhongguancun Life Science Park in Beijing, with a maximum storage capacity of 10 million samples. Adhering to the CNAS-CL10:2020 “Accreditation Criteria for Quality and Competence of Biobanks,” and integrating lessons learned from the past decade of operations at the Beijing Biobank, the Institute has developed a comprehensive quality management system for biospecimen preservation. This system achieves thorough quality control throughout the biospecimen preservation process by addressing multiple dimensions, including personnel, equipment, materials, methods, environment, and monitoring. The Institute has successfully passed the on-site inspection for the “Administrative License for Preservation of Human Genetic Resources” conducted by the Ministry of Science and Technology of China, as well as the on-site assessment by the China National Accreditation Service for Conformity Assessment (CNAS).
Chongyao Wanwei (Beijing) Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Chongyao Group, serving as the Northern Sales Headquarters in the group’s nationwide layout; it was formerly known as Beijing Wanwei Pharmaceutical Co., Ltd.
Established in 1999, the company has a registered capital of RMB 100.14 million and employs over 70 staff members. Its central logistics warehouse covers an area of more than 6,000 square meters, with a cold storage capacity of 800 cubic meters. The company holds the qualification for third-party medical device logistics in Beijing and is the only commercial enterprise in Beijing licensed to trade hazardous chemicals (anhydrous ethanol). Specializing in the wholesale of Western pharmaceutical preparations, medical devices, and chemical active pharmaceutical ingredients (APIs), it is a comprehensive pharmaceutical commerce enterprise integrating drug and medical device wholesale and distribution. The company maintains relationships with hundreds of upstream suppliers, and its sales network comprehensively covers secondary and tertiary medical institutions across Beijing. Specifically, it achieves a 95% coverage rate among tertiary-level medical institutions (with a 100% account opening rate at military hospitals) and a 65% coverage rate among secondary-level and above medical institutions, along with serving a significant number of primary healthcare institutions (including community health service centers, outpatient departments, and military medical zones). Equipped with a professional marketing team and an efficient, trustworthy sales and after-sales service team for pharmaceuticals and medical devices, the company implements localized management to provide personalized services to its clients.